Papers/Other:
- Cancer in Ontario: Open for Better. CanCertainty’s Vision and Recommendations for the 2024-28 Ontario Cancer Plan
- 2023 Ontario Budget Submission
- MacPhail, Ceilidh, and Stephanie Snow. 2022. "Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada" Current Oncology 29, no. 3: 2064-2072.
- 2022 Ontario Budget Submission
- CanCertainty Coalition COVID-19 Survey Results Summary
- Statements from Provincial Drug Plans Regarding Cancer Medication Access Challenges During COVID-19
- Budget Submission to Ontario's Minister of Finance - 2020
- Budget Submission to Ontario's Minister of Finance - 2019
- Priority Reform for Implementation of National Pharmacare: A Case for Take-Home Cancer Treatments, September 28, 2018
- Cancer Treatment Services, Auditor General of Ontario's 2017 Annual Report
- Improving the Management of Cancer in the Workplace, Discussion Paper, Chris Bonnett, H3 Consulting and Allan Smofsky, Smofsky Strategic Planning, Revised May 2018
- Budget Submission to Ontario's Minister of Finance - 2018
- Paying for Take Home Cancer Drugs in Ontario, CanCertainty and Athena Research, November 2017
- Trillium Drug Program Questions and Answers for Cancer Patients in Ontario, Developed in partnership by the Canadian Cancer Society (Ontario Provincial Office), CanCertainty, and the Ontario Ministry of Health and Long-Term Care, September 2017
- Canadian Cancer Society & CanCertainty Roundtable on Take-home Cancer Drugs, July 2017 Update
- An essential medicines list that does not include cancer drugs is not an essential medicines list, Robert Bick, June 26, 2017
- CanCertainty Position on the CAPCA pan-Canadian Cancer Drug Funding Sustainability Initiative, April 21, 2017
- Canadian Cancer Society & CanCertainty, Roundtable on Take-home Cancer Drugs, Discussion Summary, September 30, 2016
- Report Card on Cancer in Canada™, Cancer Advocacy Coalition of Canada, April 7, 2015
- Think Tank: Enhancing the Delivery of Take-Home Cancer Therapies in Ontario, Proceedings Report, Cancer Care Ontario, December 2014
- American Journal of Medicine and Medical Sciences: Benefits Outweigh Costs in Universal Healthcare: Business Case for Reimbursement of Take-home Cancer Medicines in Ontario and Atlantic Canada
- The Institutionalized Discrimination of Cancer Patients - Not What Tommy Douglas Intended: A Business Case for the Universal Coverage of Oral Cancer Medicines in Ontario and Atlantic Canada
- Canadian Partnership Against Cancer's report: Examining Disparities in Cancer Control
- Canadian Cancer Society - Manitoba Division's position paper: Cancer Treatment and Support Drugs
- The Campaign to Control Cancer's report: Spinning the Wheel
Infographics:
- #bitterestpill
- When a candidate knocks on your door, ask them where they stand on take-home cancer treatments
- More take-home treatments in pipeline for brain cancer
- More take-home treatments in pipeline for breast cancer
- More take-home treatments in pipeline for colorectal cancer
- More take-home treatments in pipeline for kidney cancer
- More take-home treatments in pipeline for leukemia
- More take-home treatments in pipeline for liver cancer
- More take-home treatments in pipeline for lung cancer
- More take-home treatments in pipeline for lymphoma
- More take-home treatments in pipeline for melanoma (French)
- More take-home treatments in pipeline for myeloma
- More take-home treatments in pipeline for ovarian cancer
- More take-home treatments in pipeline for pancreatic cancer
- More take-home treatments in pipeline for prostate cancer
- Ontario & Atlantic provinces are letting cancer patients down. It's time to level up.
- Ontario has a cancer problem
- Cost of same take-home cancer treatment by province
- Oral treatment vs. intravenous treatment